Exclusive Summary

• Rivaroxaban's original patent has expired, leading to fierce generic competition globally, yet substantial unmet market demand persists.
• The product targets critical indications like AF stroke prevention and VTE treatment, offering immense market potential, particularly in emerging markets.
• As a NOAC, it benefits from strong clinical guideline recommendations and a trend towards replacing traditional anticoagulants, demonstrating significant clinical value.
• Chinese generic pharmaceutical companies can leverage cost and quality advantages, secure international certifications, and implement differentiated strategies to gain market share worldwide.
• The Distribution model is ideal for partnering with local pharmaceutical companies to accelerate market access and promotion in various regions.